Suppr超能文献

诺氟沙星、环丙沙星、复方磺胺甲噁唑和利福昔明预防自发性细菌性腹膜炎:一项网络荟萃分析。

Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.

机构信息

Department of Gastroenterology, The Fifth Affiliated Hospital of Zhengzhou University.

Department of Gastroenterology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an.

出版信息

Eur J Gastroenterol Hepatol. 2019 Aug;31(8):905-910. doi: 10.1097/MEG.0000000000001446.

Abstract

For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, prophylactic antibiotics are recommended as a standard regimen. This study aimed to assess the efficacy of norfloxacin (N), ciprofloxacin (C), trimethoprim-sulfamethoxazole (T-S), and rifaximin (R) in the prevention of SBP. We searched the electronic databases including PubMed, Cochrane Library, Embase, and Web of Science from inception till 1 August 2018. The randomized-controlled trials that compared N, C, T-S, R, and placebo (P) were identified. A network meta-analysis (NMA) was carried out using the software STATA 14.0 and Revman 5.3. We included 16 studies involving 1984 participants in the NMA for SBP prevention. The NMA results showed that, compared with those treated with P (reference), patients treated with C, N, or R had a lower incidence of SBP and mortality. Similarly, the incidences of SBP and mortality for R were lower than those for N. The probabilities of ranking results showed that R ranked first with respect to the outcomes of the incidence of SBP and mortality. According to our results, R seemed to be the optimal regimen for protecting against SBP in patients with cirrhosis and ascites. However, considering the limitations of our study, additional high-quality studies are required in this respect.

摘要

为预防肝硬化腹水患者自发性细菌性腹膜炎(SBP),推荐使用预防性抗生素作为标准治疗方案。本研究旨在评估诺氟沙星(N)、环丙沙星(C)、复方磺胺甲噁唑(T-S)和利福昔明(R)在预防 SBP 中的疗效。我们检索了从建库到 2018 年 8 月 1 日的电子数据库,包括 PubMed、Cochrane 图书馆、Embase 和 Web of Science。纳入了比较 N、C、T-S、R 和安慰剂(P)的随机对照试验。使用 STATA 14.0 和 Revman 5.3 软件进行网络荟萃分析(NMA)。我们纳入了 16 项研究,共 1984 名参与者,进行了预防 SBP 的 NMA。NMA 结果表明,与 P 治疗组(参照组)相比,C、N 或 R 治疗组的 SBP 和死亡率较低。同样,R 治疗组的 SBP 和死亡率也低于 N 治疗组。排序结果概率显示,R 在 SBP 发生率和死亡率方面排名第一。根据我们的结果,R 似乎是预防肝硬化腹水患者 SBP 的最佳方案。然而,考虑到本研究的局限性,在这方面还需要更多高质量的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验